Log In
Friday 19th January 2018

NICE to recommend rituximab for leukaemia

5th March 2010

The National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance recommending the drug rituximab (MabThera) as a treatment for certain patients with relapsed or refractory chronic lymphocytic leukaemia.

The draft guidance recommends rituximab, in combination with fludarabine and cyclophosphamide, for the treatment of what is the most common form of leukaemia in the UK, except when the condition has not previously responded to fludarabine or has relapsed within six months of treatment, or has previously been treated with rituximab.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Article Information

Title: NICE to recommend rituximab for leukaemia
Author: Mark Nicholls
Article Id: 14272
Date Added: 5th Mar 2010


Medical News Today

Recent Related Articles

NHS approval for breast cancer drugs

A 300% increase recommended in CQC fees


Add to scrapbook
Show Comments
Add comment
Find all related articles


Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2018